Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


InfaCare raises $28 million for neonatal drug development

This article was originally published in Scrip

Executive Summary

InfaCare Pharmaceuticals has secured $28 million to advance the development its Stanate (stannsoporfin), its product for neonatal hyperbilirubinaemia. The compound is expected to enter a Phase III trial in 2009 and is the only drug in development to prevent bilirubin from reaching toxic levels in haemolysing neonates, the company says. The product inhibits haem oxygenase, an enzyme involved in bilirubin formation, and is designed to reduce the neurological risks associated with uncontrolled hyperbilirubinaemia. The series B round was led by HealthCare Ventures and Longitude Capital, which will each have a partner on InfaCare's board.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts